Ozempic, GLP-1 Medicines and ‘Healing Peptides’: What Orthopaedic Patients Should Know

Why orthopaedic patients are asking about peptides

Ozempic is a brand of semaglutide. Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts on both GIP and GLP-1 receptors. These medicines mimic naturally occurring peptide hormones involved in appetite, digestion and blood-glucose control. Product names, approved indications and doses differ, so the medicine and dose—not just the familiar brand name—should be confirmed.

They were not developed as orthopaedic drugs. Their relevance to bone and joint care comes mainly through treatment of obesity and diabetes, which can affect joint loading, mobility, inflammation, nutrition and surgical risk. The word ‘peptide’ simply describes a type of molecule; it does not mean that every peptide is proven to heal cartilage, tendons or fractures.

What semaglutide has shown in knee osteoarthritis

The strongest direct clinical evidence comes from the STEP 9 randomised trial. It enrolled 407 adults with obesity and moderate-to-severe painful knee osteoarthritis. Over 68 weeks, semaglutide 2.4 mg plus lifestyle support produced greater average weight loss than placebo plus lifestyle support (13.7% versus 3.2%) and a larger improvement in WOMAC knee-pain score (41.7 versus 27.5 points). Physical-function scores also improved more with semaglutide.

This is meaningful evidence for a particular group, but it requires the right interpretation. The trial studied semaglutide 2.4 mg, not every dose or every GLP-1 medicine. Participants had obesity, with an average BMI of about 40, and everyone received lifestyle counselling. The study did not show that semaglutide rebuilt human cartilage or corrected deformity, and gastrointestinal side effects were the commonest reason for stopping treatment.

Laboratory and animal research is exploring whether GLP-1 signalling may also affect inflammation and cartilage biology. That is an interesting research direction, not proof that semaglutide is currently a disease-modifying arthritis treatment in people.

Could weight loss delay or improve joint replacement?

For some patients, less joint load, better glucose control and improved fitness reduce symptoms enough to postpone surgery. For others, advanced joint damage continues to cause disabling pain despite successful weight loss. A lower number on the scale does not replace an examination, standing X-rays or a discussion about daily function and goals.

Recent reviews of patients having hip or knee replacement have found associations between GLP-1 use and lower early infection, revision or readmission rates. These data are encouraging, but they are largely retrospective: they cannot prove that the medicine itself caused the better outcome, and findings are not completely consistent. GLP-1 treatment should therefore be viewed as one possible component of medical optimisation—not a compulsory gateway to surgery or a guarantee of a complication-free recovery.

The hidden orthopaedic issue: muscle and nutrition

Rapid weight loss can include lean tissue as well as fat. This matters in orthopaedics because muscle strength supports balance, protects joints and helps patients mobilise after injury or surgery. Reduced appetite, nausea or vomiting can also make it difficult to obtain enough protein and micronutrients.

Older adults and patients preparing for an operation should discuss a muscle-preservation plan with the prescribing clinician. Depending on health and mobility, this may include adequate protein and energy intake, progressive resistance exercise, correction of vitamin or mineral deficiencies, and assessment for frailty or osteoporosis. Weight loss that produces weakness or malnutrition is not good surgical preparation.

• Track strength and function—not weight alone
• Report persistent nausea, vomiting, dehydration or very low food intake
• Ask whether a dietitian or supervised strengthening programme is appropriate
• Tell the orthopaedic team about unintended or very rapid weight loss

GLP-1 medicines before an anaesthetic

GLP-1 medicines can delay stomach emptying, which may leave food in the stomach despite routine fasting and increase concern about regurgitation or aspiration during anaesthesia. Current multi-society guidance does not use one blanket rule: many stable patients without significant gastrointestinal symptoms can continue treatment, while people at higher risk may need a 24-hour liquid diet, an adjusted anaesthetic plan or, occasionally, postponement of an elective procedure.

Risk may be higher during dose escalation, at higher doses, with active nausea, vomiting, bloating or constipation, or when another condition slows stomach emptying. Hospital protocols and individual circumstances differ. Do not stop or restart semaglutide or tirzepatide on your own—tell the surgeon and anaesthetist the exact medicine, dose, last-dose date and any digestive symptoms well before surgery.

What about BPC-157, TB-500 and other ‘healing peptides’?

BPC-157 and TB-500 are promoted online for tendon, ligament, muscle or fracture healing. Marketing frequently runs far ahead of clinical evidence. A 2025 systematic review of BPC-157 found 36 eligible studies: 35 were preclinical and only one was a very small retrospective human study. The review found no clinical safety data. Animal results cannot establish the effective dose, benefit or safety of an injected product in people.

There are additional concerns about sterility, contamination, incorrect concentration, immune reactions and products sold outside regulated medicine supply chains. The US FDA lists BPC-157 among bulk substances that may present significant safety risks when compounded and notes limited safety information. Regulatory rules differ by country, but the practical principle is universal: an injectable product of uncertain identity and quality should not be treated as routine orthopaedic care.

Competitive athletes also need to consider anti-doping rules. BPC-157 is included in the World Anti-Doping Agency’s prohibited category for non-approved substances. At present, we would not recommend BPC-157, TB-500 or similar internet-sourced peptides as substitutes for diagnosis, evidence-based rehabilitation or indicated surgery.

Not all peptide medicines belong in the same category

Some peptide medicines have a defined, evidence-based role. Teriparatide and abaloparatide are parathyroid-hormone-related medicines used in selected patients at very high fracture risk because they stimulate bone formation and reduce osteoporotic fractures. They are prescribed for a specific diagnosis, with recognised dosing, contraindications and monitoring.

That is very different from using an unapproved ‘healing peptide’ for a sports injury. Even established osteoporosis medicines are not routine injections for every slow-healing fracture, tendon tear or spinal fusion; their use should follow a bone-health assessment and, when appropriate, coordination with an endocrinologist or physician experienced in osteoporosis care.

A practical checklist for an orthopaedic appointment

Bring an accurate medication list rather than saying only ‘Ozempic’. Include the generic name, brand, dose, dosing day, why it was prescribed and the date of the most recent dose. Also list supplements, compounded products and peptides—there is no judgement in disclosing them, and knowing exactly what you use makes care safer.

• Clarify the diagnosis before assuming weight or inflammation explains the pain
• Use GLP-1 treatment only through an appropriately qualified prescriber
• Protect protein intake, strength and bone health during weight loss
• Discuss the perioperative plan early with the prescriber, surgeon and anaesthetist
• Avoid unregulated injectable peptides and products with unverifiable ingredients